©2024 Stanford Medicine
Pulmonary Hypertension Association Registry
Recruiting
I'm InterestedTrial ID: NCT04071327
Purpose
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial
hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects
information from people with PAH and CTEPH who are cared for in participating PHA-accredited
Pulmonary Hypertension Care Centers throughout the U.S.
PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and
will observe how well these participants do. The goal is to see if people with PH are treated
according to recommended guidelines, and to see if there are certain factors that can lead to
better or worse outcomes.
PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at
participating PHA-accredited PH Care Centers. PHAR contains data about patient care and
outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status;
socioeconomic status; diagnosis test results; body size; treatment information; interest in
participating in clinical trials; family health and social history; and information about
smoking, alcohol, or drug use. Participants are followed over time, and provide updates such
as changes in therapy, how often participants need to go to the hospital, and survival. Such
information may help healthcare providers provide better care.
Official Title
Pulmonary Hypertension Association Registry
Stanford Investigator(s)
Roham Zamanian
Professor of Medicine (Pulmonary and Critical Care Medicine)
Eligibility
Inclusion Criteria:
- All age groups
- Written informed consent
- Pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension
(CTEPH), or pediatric PH due to developmental lung disease
- Within 6 months of first outpatient visit at a PH Care Center
Exclusion Criteria:
- Diagnosis of WSPH Group 2 pulmonary hypertension
- Diagnosis of WSPH Group 3 pulmonary hypertension, except PH due to developmental lung
disease
- Diagnosis of WSPH Group 5 pulmonary hypertension
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Roham T. Zamanian, MD